From left: Dr Waleed Faisal of ArrayPatch, and Prof Abina Crean of UCC and Rinn Pharma & BioPharma. Image: Rinn Pharma & BioPharma
The project’s goals include the improvement of treatment effectiveness while minimising side effects by using microneedles to deliver drugs more precisely.
A new collaboration between Research Ireland’s Rinn Pharma & Biopharma (RP&B) and Cork-based biotech spin-out ArrayPatch will focus on developing a novel skin cancer treatment using a patented dissolvable microneedle platform.
‘DerMap-V’ aims to deliver therapeutic agents directly to target tissues in a painless and efficient manner, according to its makers, and is currently being advanced across a growing pipeline – including applications in metabolic disorders, weight loss and nail fungal infections.
The collaboration between RP&B and ArrayPatch will be hosted at University College Cork (UCC) and led by Professor Abina Crean and ArrayPatch founder Dr Waleed Faisal. Its goals include the improvement of treatment effectiveness while minimising side effects by using microneedles to deliver drugs more precisely.
